These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 35280362)
1. Genomic landscape and prognosis of patients with Fan Z; Zhang Q; Feng L; Wang L; Zhou X; Han J; Li D; Liu J; Zhang X; Zuo J; Zou X; Cai Y; Sun Y; Wang Y Ann Transl Med; 2022 Feb; 10(4):188. PubMed ID: 35280362 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma. Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759 [TBL] [Abstract][Full Text] [Related]
3. Xue D; Lin H; Lin L; Wei Q; Yang S; Chen X Transl Cancer Res; 2021 Mar; 10(3):1284-1294. PubMed ID: 35116455 [TBL] [Abstract][Full Text] [Related]
4. The co-mutation of Zhang Y; Li S; Lyu Z; Cai J; Zheng N; Li Y; Xu T; Zeng H J Thorac Dis; 2022 Jan; 14(1):185-193. PubMed ID: 35242380 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer. Wang L; Diao M; Zhang Z; Jiang M; Chen S; Zhao D; Liu Z; Zhou C Lung Cancer; 2024 Jan; 187():107439. PubMed ID: 38113653 [TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of STK11 with different mutation status and its relationship with tumor-infiltrating immune cells in non-small cell lung cancer. Zheng J; Deng Y; Huang B; Chen X Front Immunol; 2024; 15():1387896. PubMed ID: 38736875 [TBL] [Abstract][Full Text] [Related]
7. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with Fu J; Li Y; Li C; Tong Y; Li M; Cang S Transl Cancer Res; 2021 Sep; 10(9):3963-3978. PubMed ID: 35116695 [TBL] [Abstract][Full Text] [Related]
8. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer. Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q Front Oncol; 2021; 11():751106. PubMed ID: 35273907 [TBL] [Abstract][Full Text] [Related]
9. YTHDF1 Promotes Cyclin B1 Translation through m Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W Cells; 2021 Jul; 10(7):. PubMed ID: 34359836 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. Zengin T; Önal-Süzek T J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672117 [TBL] [Abstract][Full Text] [Related]
11. Co-mutation of TP53 and TTN is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma. Ying K; Zou L; Wang D; Wang R; Qian J Comb Chem High Throughput Screen; 2023 Oct; ():. PubMed ID: 37904553 [TBL] [Abstract][Full Text] [Related]
12. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation. Zeng D; Hu Z; Yi Y; Valeria B; Shan G; Chen Z; Zhan C; Lin M; Lin Z; Wang Q BMC Pulm Med; 2021 Oct; 21(1):316. PubMed ID: 34635074 [TBL] [Abstract][Full Text] [Related]
13. TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes. Wang P; Wang F; He H; Chen Y; Lin H; Chen P; Chen X; Liu S Ann Transl Med; 2021 Aug; 9(16):1330. PubMed ID: 34532467 [TBL] [Abstract][Full Text] [Related]
14. The prognostic value of tumor mutation burden in Jiao XD; He X; Qin BD; Liu K; Wu Y; Liu J; Hou T; Zang YS J Thorac Dis; 2019 Nov; 11(11):4507-4515. PubMed ID: 31903239 [TBL] [Abstract][Full Text] [Related]
15. LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC. Liu T; Xu S; Liu X Oncol Lett; 2022 Feb; 23(2):55. PubMed ID: 34992687 [TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393 [TBL] [Abstract][Full Text] [Related]
17. TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival. Freudenstein D; Litchfield C; Caramia F; Wright G; Solomon BJ; Ball D; Keam SP; Neeson P; Haupt Y; Haupt S Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545367 [TBL] [Abstract][Full Text] [Related]
18. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma. Zhou S; Wang P; Su X; Chen J; Chen H; Yang H; Fang A; Xie L; Yao Y; Yang J PLoS One; 2017; 12(10):e0187356. PubMed ID: 29088286 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. Qin K; Hou H; Liang Y; Zhang X BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384 [TBL] [Abstract][Full Text] [Related]
20. Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma. Yin D; Zhang Y; Li H; Cheng L Clin Respir J; 2023 Dec; 17(12):1301-1315. PubMed ID: 37985446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]